Screening for germline EGFR T790M mutations through lung cancer genotyping

Journal of Thoracic Oncology

Volumn 7, Issue 6, 2012, Pages 1049-1052

  Oxnard, Geoffrey R ^a   Miller, Vincent A ^a   Robson, Mark E ^a   Azzoli, Christopher G ^a   Pao, William ^b   Ladanyi, Marc ^a   Arcila, Maria E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; GENETIC SCREENING; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; MUTATION; PRIORITY JOURNAL;

EID: 84861302770     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318250ed9d     Document Type: Article

References (18)

1. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-622. (Pubitemid 351601203)
2. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-1316. (Pubitemid 41722184)
3. Ikeda K, Nomori H, Mori T, Sasaki J, Kobayashi T. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 2008;85:1430-1432. (Pubitemid 351381643)
4. Vikis H, Sato M, James M, et al. EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res 2007;67:4665-4670. (Pubitemid 46910171)
5. Amos CI, Pinney SM, Li Y, et al. A susceptibility locus on chromosome 6q greatly increases lung cancer risk among light and never smokers. Cancer Res 2010;70:2359-2367.
6. Girard N, Lou E, Azzoli CG, et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res 2010;16:755-763.
7. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
8. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011;17:5530-5537.
9. D'Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066-2070.
10. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011;17:1169-1180.
11. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59.
12. Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-440.
13. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.
14. Burt RW, Barthel JS, Dunn KB, et al.; NCCN. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010;8:8-61.
15. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009;4:e7887.
16. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
17. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-134.
18. Cancer Genome Atlas T. Integrated genomic analyses of ovarian carcinoma Nature 2011 474:609-615.